Last reviewed · How we verify
Alogliptin and glimepiride
Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and glimepiride is a sulfonylurea that stimulates insulin release.
Alogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and glimepiride is a sulfonylurea that stimulates insulin release. Used for Type 2 diabetes.
At a glance
| Generic name | Alogliptin and glimepiride |
|---|---|
| Also known as | SYR-322, Amaryl |
| Sponsor | Takeda |
| Drug class | DPP-4 inhibitor and sulfonylurea |
| Target | DPP-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
Alogliptin works by blocking the action of DPP-4, an enzyme that breaks down incretin hormones, thereby increasing the levels of incretin hormones. Glimepiride, on the other hand, stimulates insulin release from the pancreatic beta cells, thereby lowering blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Hypoglycemia
- Nausea
- Diarrhea
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Comparison of Type 2 Diabetes Pharmacotherapy Regimens
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes
- Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination (PHASE4)
- Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors (PHASE4)
- Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alogliptin and glimepiride CI brief — competitive landscape report
- Alogliptin and glimepiride updates RSS · CI watch RSS
- Takeda portfolio CI